Literature DB >> 27037202

A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio.

Bobby V M Dasari1, Keith J Roberts1, James Hodson2, Lewis Stevens3, Andrew M Smith3, Stefan G Hubscher4, John Isaac1, Paolo Muiesan1, Robert P Sutcliffe1, Ravi Marudanayagam1, Darius F Mirza5.   

Abstract

BACKGROUND: Site of tumour origin, lymph node metastases and lymph node ratio (LNR) are identified as important factors determining prognosis in patients undergoing pancreaticoduodenectomy (PD). This study hypothesised that a prognostic index to predict survival could be developed through statistical modelling based on these pathological variables.
METHODS: Patients who underwent PD between 2004 and 2013 were included. Univariable and multivariable (Cox regression) analyses were performed to identify predictors of survival, and a prognostic index was derived. The prognostic index was then validated using an external patient cohort.
RESULTS: A total of 567 patients who underwent PD were used as a derivation cohort. Tumour site (p < 0.001), tumour size (p = 0.002), T-stage (p < 0.001), vascular involvement (p = 0.002), number of positive nodes (p < 0.001) and LNR (p < 0.001) were significantly associated with survival in univariable analysis. LNR (p < 0.001), tumour site (p < 0.001), T-stage (p = 0.007) remained significant predictors of survival in multivariable analysis, and were combined to derive a prognostic index. The accuracy of the prognostic index was assessed both on the original cohort, and a validation set of 194 patients from another institutional prospective database. The AUROC scores for predicting the overall survival at 3 years were 0.77 in the derivation cohort and 0.74 in the validation cohort.
CONCLUSION: The Pancreaticoduodenectomy Prognostic Index is a validated clinico-pathological model based on tumour site, T-stage and LNR to predict long-term survival following PD.
Copyright © 2016 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27037202      PMCID: PMC4814610          DOI: 10.1016/j.hpb.2015.11.008

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  26 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

5.  Survival and prognostic factors in pancreatic and ampullary cancer.

Authors:  Johannes Lemke; Désirée Schäfer; Silvia Sander; Doris Henne-Bruns; Marko Kornmann
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

Review 6.  Distal cholangiocarcinoma.

Authors:  Paxton V Dickson; Stephen W Behrman
Journal:  Surg Clin North Am       Date:  2014-04       Impact factor: 2.741

7.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

8.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

9.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

10.  Predictors of survival in periampullary cancers following pancreaticoduodenectomy.

Authors:  Ioannis Hatzaras; Nathaniel George; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2010-01-28       Impact factor: 5.344

View more
  6 in total

1.  An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival.

Authors:  Steven Walczak; Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2017-08-03       Impact factor: 3.452

Review 2.  Pancreaticoduodenectomy for periampullary tumours: a review article based on Surveillance, End Results and Epidemiology (SEER) database.

Authors:  S K Kamarajah
Journal:  Clin Transl Oncol       Date:  2018-01-15       Impact factor: 3.405

3.  The impact of the lymph node density on overall survival in patients with Wilms' tumor: a SEER analysis.

Authors:  Haisheng You; Jin Yang; Qingqing Liu; Lina Tang; Qingting Bu; Zhenyu Pan; Jun Lyu
Journal:  Cancer Manag Res       Date:  2018-04-06       Impact factor: 3.989

4.  Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessment.

Authors:  Chaobin He; Shuxin Sun; Yu Zhang; Xiaojun Lin; Shengping Li
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

5.  A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer.

Authors:  Alison Bradley; Robert Van Der Meer; Colin J McKay
Journal:  BMJ Open       Date:  2019-08-21       Impact factor: 2.692

Review 6.  Application of artificial intelligence to pancreatic adenocarcinoma.

Authors:  Xi Chen; Ruibiao Fu; Qian Shao; Yan Chen; Qinghuang Ye; Sheng Li; Xiongxiong He; Jinhui Zhu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.